Edgewise Therapeutics
Brooke Harrison is currently serving as the Vice President of Medical Writing at Edgewise Therapeutics. Prior to this role, Brooke held various positions in medical writing and regulatory affairs at companies such as Novo Nordisk, Forma Therapeutics, and Clinipace. With a background in integrative physiology and exercise physiology, Brooke has also worked in research and clinical roles at institutions like University of Colorado Boulder, Gilead Sciences, and Myogen, Inc. Additionally, Brooke is the owner and consultant at Boulder Medical Writing, LLC, showcasing a diverse and extensive career in the medical field.
This person is not in the org chart
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.